The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Head and Neck Oncology

Volumn 3, Issue 1, 2011, Pages

  Chau, Nicole G ^a   Perez Ordonez, Bayardo ^a   Zhang, Katherine ^a   Pham, Nhu An ^a   Ho, James ^a   Zhang, Tong ^a   Ludkovski, Olga ^a   Wang, Lisa ^a   Chen, Eric X ^a   Tsao, Ming Sound ^a   Kamel Reid, Suzanne ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ISPINESIB; PROTEIN P16; SCATTER FACTOR RECEPTOR; SORAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ADOLESCENT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WART VIRUS; ADULT; BIOSYNTHESIS; CARCINOMA; COHORT ANALYSIS; DRUG ANTAGONISM; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VIROLOGY;

ADOLESCENT; ADULT; AGED; CARCINOMA; COHORT STUDIES; FEMALE; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 79951952444     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-3-11     Document Type: Article

References (49)

1. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. JR Grandis DJ Tweardy, Cancer Res 1993 53 3579 3584 8339264 (Pubitemid 23229640)
2. The epidermal growth factor receptor and its inhibition in cancer therapy. JR Woodburn, Pharmacol Ther 1999 82 241 250 10.1016/S0163-7258(98) 00045-X 10454201 (Pubitemid 29255919)
3. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. S Temam H Kawaguchi AK El-Naggar J Jelinek H Tang DD Liu W Lang JP Issa JJ Lee L Mao, J Clin Oncol 2007 25 2164 2170 10.1200/JCO.2006.06.6605 17538160 (Pubitemid 46954638)
4. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. CH Chung K Ely L McGavran M Varella-Garcia J Parker N Parker C Jarrett J Carter BA Murphy J Netterville, et al. J Clin Oncol 2006 24 4170 4176 10.1200/JCO.2006.07.2587 16943533 (Pubitemid 46622295)
5. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem, et al. NEnglJ Med 2006 354 567 578 10.1056/NEJMoa053422 (Pubitemid 43209104)
6. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. EE Cohen F Rosen WM Stadler W Recant K Stenson D Huo EE Vokes, J Clin Oncol 2003 21 1980 1987 10.1200/JCO.2003.10.051 12743152 (Pubitemid 46606387)
7. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. LL Siu D Soulieres EX Chen GR Pond SF Chin P Francis L Harvey M Klein W Zhang J Dancey, et al. J Clin Oncol 2007 25 2178 2183 10.1200/JCO.2006.07.6547 17538162 (Pubitemid 46954640)
8. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. D Soulieres NN Senzer EE Vokes M Hidalgo SS Agarwala LL Siu, J Clin Oncol 2004 22 77 85 10.1200/JCO.2004.06.075 14701768 (Pubitemid 41095117)
9. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. B Burtness MA Goldwasser W Flood B Mattar AA Forastiere, J Clin Oncol 2005 23 8646 8654 10.1200/JCO.2005.02.4646 16314626 (Pubitemid 46211507)
10. Platinum-based chemotherapy plus cetuximab in head and neck cancer. JB Vermorken R Mesia F Rivera E Remenar A Kawecki S Rottey J Erfan D Zabolotnyy HR Kienzer D Cupissol, et al. N Engl J Med 2008 359 1116 1127 10.1056/NEJMoa0802656 18784101
11. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. MV Grandal R Zandi MW Pedersen BM Willumsen DB van HS Poulsen, Carcinogenesis 2007 28 1408 1417 10.1093/carcin/bgm058 17372273 (Pubitemid 47241789)
12. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. HS Huang M Nagane CK Klingbeil H Lin R Nishikawa XD Ji CM Huang GN Gill HS Wiley WK Cavenee, J Biol Chem 1997 272 2927 2935 10.1074/jbc.272.5.2927 9006938 (Pubitemid 27053343)
13. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. R Nishikawa XD Ji RC Harmon CS Lazar GN Gill WK Cavenee HJ Huang, Proc Natl Acad Sci USA 1994 91 7727 7731 10.1073/pnas.91.16.7727 8052651 (Pubitemid 24238258)
14. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. H Ji X Zhao Y Yuza T Shimamura D Li A Protopopov BL Jung K McNamara H Xia KA Glatt, et al. Proc Natl Acad Sci USA 2006 103 7817 7822 10.1073/pnas.0510284103 16672372
15. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. JC Sok FM Coppelli SM Thomas MN Lango S Xi JL Hunt ML Freilino MW Graner CJ Wikstrand DD Bigner, et al. Clin Cancer Res 2006 12 5064 5073 10.1158/1078-0432.CCR-06-0913 16951222 (Pubitemid 44453332)
16. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. ML Gillison WM Koch RB Capone M Spafford WH Westra L Wu ML Zahurak RW Daniel M Viglione DE Symer, et al. J Natl Cancer Inst 2000 92 709 720 10.1093/jnci/92.9.709 10793107 (Pubitemid 30365531)
17. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. W Shi H Kato B Perez-Ordonez M Pintilie S Huang A Hui B O'Sullivan J Waldron B Cummings J Kim, et al. J Clin Oncol 2009 27 6213 6221 10.1200/JCO.2009.23.1670 19884544
18. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. ML Gillison G D'Souza W Westra E Sugar W Xiao S Begum R Viscidi, J Natl Cancer Inst 2008 100 407 420 10.1093/jnci/djn025 18334711 (Pubitemid 351480511)
19. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. WH Westra JM Taube ML Poeta S Begum D Sidransky WM Koch, Clin Cancer Res 2008 14 366 369 10.1158/1078-0432.CCR-07-1402 18223210 (Pubitemid 351226102)
20. Molecular classification identifies a subset of human papillomavirus - associated oropharyngeal cancers with favorable prognosis. PM Weinberger Z Yu BG Haffty D Kowalski M Harigopal J Brandsma C Sasaki J Joe RL Camp DL Rimm A Psyrri, J Clin Oncol 2006 24 736 747 10.1200/JCO.2004.00.3335 16401683 (Pubitemid 46622040)
21. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. C Fakhry WH Westra S Li A Cmelak JA Ridge H Pinto A Forastiere ML Gillison, J Natl Cancer Inst 2008 100 261 269 10.1093/jnci/djn011 18270337 (Pubitemid 351480538)
22. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. B Kumar KG Cordell JS Lee FP Worden ME Prince HH Tran GT Wolf SG Urba DB Chepeha TN Teknos, et al. J Clin Oncol 2008 26 3128 3137 10.1200/JCO.2007.12.7662 18474878
23. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. P Lassen JG Eriksen S Hamilton-Dutoit T Tramm J Alsner J Overgaard, J Clin Oncol 2009 27 1992 1998 10.1200/JCO.2008.20.2853 19289615
24. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. EM Smith D Wang Y Kim LM Rubenstein JH Lee TH Haugen LP Turek, Oral Oncol 2008 44 133 142 10.1016/j.oraloncology.2007.01.010 17360226 (Pubitemid 351179656)
25. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. LM Knowles LP Stabile AM Egloff ME Rothstein SM Thomas CT Gubish EC Lerner RR Seethala S Suzuki KM Quesnelle, et al. Clinical Cancer Research 2009 15 3740 3750 10.1158/1078-0432.CCR-08-3252 19470725
26. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. YS Chen JT Wang YF Chang BY Liu YP Wang A Sun CP Chiang, Journal of Oral Pathology & Medicine 2004 33 209 217 (Pubitemid 38478507)
27. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. C Allen S Duffy T Teknos M Islam Z Chen PS Albert G Wolf WC Van, Clin Cancer Res 2007 13 3182 3190 10.1158/1078-0432.CCR-06-3047 17545521 (Pubitemid 46944900)
28. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. MF Di Renzo M Olivero T Martone A Maffe P Maggiora AD Stefani G Valente S Giordano G Cortesina PM Comoglio, Oncogene 2000 19 1547 1555 10.1038/sj.onc.1203455 10734314 (Pubitemid 30175676)
29. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. DL Wheeler S Huang TJ Kruser MM Nechrebecki EA Armstrong S Benavente V Gondi KT Hsu PM Harari, Oncogene 2008 27 3944 3956 10.1038/onc.2008.19 18297114 (Pubitemid 351913636)
30. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. PA Tang LL Siu EX Chen SJ Hotte S Chia JK Schwarz GR Pond C Johnson AD Colevas TW Synold, et al. Invest New Drugs 2008 26 257 264 10.1007/s10637-007-9098-8 18038218
31. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. C Elser LL Siu E Winquist M Agulnik GR Pond SF Chin P Francis R Cheiken J Elting A McNabola, et al. J Clin Oncol 2007 25 3766 3773 10.1200/JCO.2006.10.2871 17704426 (Pubitemid 47372619)
32. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. PM Weinberger Z Yu BG Haffty D Kowalski M Harigopal C Sasaki DL Rimm A Psyrri, Clin Cancer Res 2004 10 5684 5691 10.1158/1078-0432.CCR-04-0448 15355894 (Pubitemid 39180943)
33. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. M Agulnik SG da Cunha D Hedley T Nicklee PP Dos Reis J Ho GR Pond H Chen S Chen Y Shyr, et al. Journal of Clinical Oncology 2007 25 2184 2190 10.1200/JCO.2006.07.6554 17538163 (Pubitemid 46954641)
34. Erlotinib in lung cancer - molecular and clinical predictors of outcome. MS Tsao A Sakurada JC Cutz CQ Zhu S Kamel-Reid J Squire I Lorimer T Zhang N Liu M Daneshmand, et al. N Engl J Med 2005 353 133 144 10.1056/NEJMoa050736 16014883 (Pubitemid 41058345)
35. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini, et al. J Natl Cancer Inst 2005 97 643 655 10.1093/jnci/dji112 15870435 (Pubitemid 40812628)
36. The EGFRvIII variant in squamous cell carcinomas of the head and neck: Expression and correlation with clinico-pathological parameters in 681 patients from the randomised DAHANCA 6/7 study. JGLP Eriksen J Overgaard, ECCO 15 - 34th ESMO Multidisciplinary Congress Berlin 2009 472 September 2009
37. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. SA Prigent M Nagane H Lin I Huvar GR Boss JR Feramisco WK Cavenee HS Huang, J Biol Chem 1996 271 25639 25645 10.1074/jbc.271.41.25639 8810340 (Pubitemid 26337944)
38. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. PH Huang A Mukasa R Bonavia RA Flynn ZE Brewer WK Cavenee FB Furnari FM White, Proc Natl Acad Sci USA 2007 104 12867 12872 10.1073/pnas.0705158104 17646646 (Pubitemid 47255246)
39. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute, et al. N Engl J Med 2005 353 2012 2024 10.1056/NEJMoa051918 16282176 (Pubitemid 41609094)
40. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. CE Pelloski KV Ballman AF Furth L Zhang E Lin EP Sulman K Bhat JM McDonald WK Yung H Colman, et al. J Clin Oncol 2007 25 2288 2294 10.1200/JCO.2006.08.0705 17538175 (Pubitemid 46954657)
41. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. N Shinojima K Tada S Shiraishi T Kamiryo M Kochi H Nakamura K Makino H Saya H Hirano J Kuratsu, et al. Cancer Res 2003 63 6962 6970 14583498 (Pubitemid 37322983)
42. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. AB Heimberger R Hlatky D Suki D Yang J Weinberg M Gilbert R Sawaya K Aldape, Clin Cancer Res 2005 11 1462 1466 10.1158/1078-0432.CCR-04-1737 15746047 (Pubitemid 40315227)
43. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. L Liu LM Backlund BR Nilsson D Grander K Ichimura HM Goike VP Collins, J Mol Med 2005 83 917 926 10.1007/s00109-005-0700-2 16133418 (Pubitemid 41598692)
44. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. DA Eberhard G Giaccone BE Johnson, J Clin Oncol 2008 26 983 994 10.1200/JCO.2007.12.9858 18281673 (Pubitemid 351398092)
45. PIK3CA mutation associates with improved outcome in breast cancer. K Kalinsky LM Jacks A Heguy S Patil M Drobnjak UK Bhanot CV Hedvat TA Traina D Solit W Gerald ME Moynahan, Clin Cancer Res 2009 15 5049 5059 10.1158/1078-0432.CCR-09-0632 19671852
46. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens RS Herbst WL Ince PA Janne T Januario DH Johnson, et al. J Clin Oncol 2005 23 5900 5909 10.1200/JCO.2005.02.857 16043828
47. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. FA Shepherd MS Tsao, J Clin Oncol 2006 24 1219 1220 author reply 1220-1211 10.1200/JCO.2005.04.4420 16505443 (Pubitemid 46638822)
48. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. ML Lo R Leonardi MD Mignogna G Pannone C Rubini T Pieramici L Trevisiol F Ferrari R Serpico N Testa, et al. Anticancer Research 2004 24 1063 1069 15154624 (Pubitemid 38624939)
49. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. K Yoshimoto J Dang S Zhu D Nathanson T Huang R Dumont DB Seligson WH Yong Z Xiong N Rao, et al. Clin Cancer Res 2008 14 488 493 10.1158/1078-0432.CCR-07-1966 18223223 (Pubitemid 351226117)